Replies to post #22228 on $heff's $tation of $tocks & $olid DD

[$heff]

w/ NVLT ($1.77) I feel strongly about the outcome of the Phase III study. I know what the standard of care is in treating (NSCLC) non-small cell lung cancer and it is carbo+taxol. Carbo+Taxol has been the standard of care the past decade. Avasting showed 12 months OS when compared w/ Carbo+Taxol and now that is the standard.
"The excitement is driven by the fact that the company extended the length of the trial because patients lived longer than expected. Lung cancer is especially virulent, and previous studies at other companies have found that the control group — those not receiving the study drug — have lived an average of 9.8 months. Novelos’ goal for the trial is to extend survival for the treatment group — the ones who would take the drug — by 25 percent to 12.5 months."

2)What merits consideration is the study being done w/ Carbo+Taxol w/ addition of Nov002. Nothing else matters.

It's all about risk vs. reward. If the results dont measure up and I lose half my investment then that is the risk I will take. If the results are what I believe they are, then this stock will blow past its current levels and NVLT will accelerate the partnership potentials w/ other companies looking to capitalize on the most deadly of all tumor types in NSCLC and buyout NOV002. It is that simple. The study was blinded so no one knows what the outcome will be...even folks who claim to have an idea. Best, $heff


Message in reply to:

$heff - with NVLT (1.77) I would appreciate your comment on couple of items:

1. I see that you took a position at 1.97. From a technical perspective, the stock was overbought at this level and was proven by the retracement that occurred over the past couple of days. Do you feel so strongly about the outcome of Phase III, that you took a Buffett-esque approach and didn't worry about your entry point?

2. A lot of people are drawing analogies between PARD and NVLT, including the illustrious Adam F (who single-handedly tanked ANX today). What are your thoughts on this? I know PARD used chemo OR Picoplatin and NVLT uses chemo PLUS NOV 002 so it is not an apples to apples comparison , but it does merit consideration.

Full disclosure - I took a position in NVLT at 1.79 today. I think its a risk, but the reward could be enormous.

Thanks in advance for your thoughts!

-BR